Evofem amends Series F-1 Preferred; conversion price set at $0.0154, adjustment provisions removed

Evofem Biosciences, Inc.

Amended Certificate of Designation removes Section 8(h) adjustment provisions from Series F-1 Preferred.
Conversion Price changed to $0.0154 per share; previously subject to adjustment.
Approved by unanimous written consent of Required Holders.
Filed with Delaware Secretary of State on June 20, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.